Re: Farmas USA
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.44%) on 26,952,609 shares traded after ARIAD Announced Discontinuation of the Phase 3 Epic Trial of Iclusig in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-89.46%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.
To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)
esto es lo que ha bajado la accion!!